How does McKesson make money?

MCKESSON CORP – Business Breakdown

The Essentials

McKesson Corporation is a large-scale healthcare infrastructure business whose economic role is centered on pharmaceutical distribution, technology-enabled medication access, and medical-surgical supply logistics. Based on the filings, the company operates through a concentrated U.S.-led platform with four principal operating areas: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions (RxTS), and Medical-Surgical Solutions, plus a residual “Other” category following the Norway divestiture. The business is highly material in scale, with total revenues of $306.4 billion for the nine months ended December 31, 2025, and the North American Pharmaceutical segment alone accounting for 84.1% of that total.

From an investor perspective, McKesson is best understood as a distribution and workflow intermediary embedded in the healthcare supply chain rather than as a high-IP, high-margin technology or branded product company. Its value proposition is operational breadth, logistics scale, and connectivity across pharmacies, providers, payors, and biopharma participants. The filings also indicate an active portfolio reshaping effort, including the planned separation of Medical-Surgical Solutions and the completed divestiture of Norway operations, suggesting a continued emphasis on sharpening the business mix around core North American healthcare distribution and services.

Business Model & Revenue Drivers

McKesson generates economic value through a combination of high-volume distribution, service fees, and technology-enabled transaction facilitation across healthcare channels. The revenue base is heavily concentrated, and the filings make clear that segment mix is the key determinant of operating profile.

• North American Pharmaceutical — $257.5 billion, 84.1% of revenue

  • The core engine of the company.
  • Distributes branded, generic, and specialty drugs to wholesalers and institutions in the U.S. and Canada.
  • Also provides pharmacy solutions, making this segment both a logistics platform and a service layer for downstream customers.
  • Its scale makes it the dominant contributor to revenue and the primary driver of operating leverage.

• Oncology & Multispecialty — $35.7 billion, 11.6% of revenue

  • Supports community oncology and specialty practices.
  • Revenue is tied to management services, technology, and clinical support.
  • This segment appears strategically important because it extends McKesson beyond pure distribution into more embedded practice-level services.

• Prescription Technology Solutions (RxTS) — $4.3 billion, 1.4% of revenue

  • Connects patients, pharmacies, providers, PBMs, health plans, and biopharma.
  • The segment’s economic role is to facilitate medication access and affordability through networked transaction infrastructure.
  • While small in revenue terms, it is strategically relevant as a connectivity and workflow platform.

• Medical-Surgical Solutions — $8.6 billion, 2.8% of revenue

  • Supplies medical-surgical products and logistics to physician offices, surgery centers, and nursing homes.
  • The company announced a separation of this business into an independent company on May 8, 2025.
  • This suggests management views the segment as non-core relative to the broader portfolio.

• Other — $0.9 billion, 0.3% of revenue

  • Residual operations following the Norway divestiture completed on January 30, 2026.
  • This category is not a meaningful earnings driver and mainly reflects portfolio cleanup.

Geographically, the business is overwhelmingly U.S.-centric, with approximately 92–95% of revenues derived from the United States. Foreign exposure is limited and appears to be shrinking following divestitures. This concentration reinforces the company’s dependence on U.S. healthcare distribution economics, regulatory conditions, and reimbursement dynamics.

Strategic Edge & Market Positioning

McKesson’s competitive position is best characterized as strong execution within a commoditized industry rather than a business protected by a durable structural moat.

Economic Moat: Limited / Not clearly evidenced

• Switching costs: The filings indicate low switching costs for customers such as pharmacies and providers, who can shift distributors based on price and service.
• Network effects: No meaningful network effects are identified.
• Intangible assets: The company holds patents, trademarks, and copyrights, but these are not described as central to the business model or as a source of durable pricing power.
• Cost leadership: McKesson benefits from scale, distribution centers, and automation, but the filings explicitly suggest these advantages are replicable and not uniquely protected.

Execution Advantage: Evident

• The company appears to compete on operational reliability, breadth of offering, and logistics efficiency.
• Its scale in pharmaceutical distribution likely supports purchasing and fulfillment efficiency.
• Automation investments and facility optimization suggest management is focused on execution-driven margin discipline rather than moat expansion.
• Competitive pressure remains intense, with Cencora and Cardinal Health identified as major rivals in pharmaceutical distribution.

In short, McKesson’s market position is anchored in scale and operational competence, not in a defensible franchise structure. That distinction matters: the business can be highly cash-generative, but its economics are exposed to pricing competition, service differentiation, and regulatory friction.

Outlook & Innovation Pipeline

The filings do not provide a detailed three-year strategic roadmap or a clearly articulated innovation pipeline. However, several directional priorities are evident.

• Portfolio simplification and focus

  • The company is actively reshaping its asset base through divestitures and separations.
  • Norway has been sold, Canadian retail has been held for sale, and Medical-Surgical Solutions is slated for separation.
  • This points to a deliberate move toward a more focused core around North American pharmaceutical distribution and adjacent services.

• Operational efficiency

  • Management is pursuing cost optimization, headcount reductions, and facility exits.
  • The filings reference restructuring charges, indicating that efficiency and margin discipline are central to the near-term agenda.

• Growth emphasis in core platforms

  • North American Pharmaceutical remains the primary scale engine.
  • Oncology & Multispecialty appears to be a strategic adjacency with potential for deeper clinical and technology integration.
  • RxTS continues to serve as a connectivity layer across the medication access ecosystem.

• Technology and innovation

  • The filings mention investments in distribution centers and technology/automation.
  • However, no specific patents, breakthrough technologies, or R&D-led initiatives are identified as material future growth drivers.
  • Innovation appears operational rather than scientific: process automation, logistics optimization, and workflow connectivity rather than proprietary product development.

Overall, the forward view implied by the filings is one of disciplined portfolio management, compliance-heavy execution, and incremental operational improvement rather than transformative innovation. For sophisticated investors, the key question is less about disruptive growth and more about whether McKesson can continue to convert scale into stable cash generation while managing litigation, regulatory, and restructuring complexity.